Innate Pharma SA (FR:IPH) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Innate Pharma SA has unveiled promising data from its TELLOMAK Phase 2 study, highlighting the potential of lacutamab to improve the quality of life for patients with cutaneous T-cell lymphoma. The study shows significant alleviation of symptoms such as severe itching and skin infections, offering hope for those with limited treatment options.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
